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We appreciate the comments of Haylor and Morcos.the contrast agent itself. In humans, only a 2.5-fold in-
Regarding the issue of the nonselective endothelin (ET)crease in plasma ET-1 is required to decrease GFR,
antagonist, SB209670, evaluated in our study [1], phar-an effect mediated through the ETA receptor [3]. The
macokinetic data confirmed that mean immunoreactiveobservation that contrast nephropathy was exacerbated
plasma ET-1 levels were higher in the patients treatedin patients receiving SB209670 is not surprising and sug-
with SB209670 compared to the placebo group. Plasmagests the absence of functional ETA receptor antagonism concentration of ET-1 was significantly increased through-by this drug.
out the 12-hour infusion of SB209670 and remained ele-
SB 209670 was administered by a 12-hour intravenous
vated at 24 hours compared to placebo. Thus, the exacer-
infusion providing acute receptor antagonism, but the bation of contrast nephrotoxicity after treatment with
drug would have been virtually undetectable in plasma a nonselective ET receptor antagonist may be due to
when contrast nephropathy was determined from the 48- increased plasma ET-1 concentrations. Whether a selec-
hour serum creatinine [2]. The importance of sustained tive ETA receptor antagonist is effective for the preven-
drug cover in preventing human contrast nephropathy tion of contrast nephrotoxicity remains to be determined
has been demonstrated previously with the calcium an- by a randomized clinical trial.
tagonist nitrendipine. A protective response was obtained Regarding the duration of treatment with SB209670,
with a daily dose of 20 mg (3 days) while a single 20 mg previous animal studies of contrast nephrotoxicity have
dose administered prior to contrast injection was ineffec- found that plasma ET-1 concentration increased signifi-
tive [4]. To study the effect of an ET receptor antagonist cantly within minutes of radiocontrast injection, but re-
on contrast nephropathy, ET receptor antagonism should turned to baseline at 30 minutes after injection [2]. To
be sustained for at least 48 hours after contrast delivery. date, no vasodilator agent has been found to prevent
We believe that multiple dosing with an orally admin- radiocontrast nephrotoxicity and the potential benefit of
istered ETA selective antagonist should be clinically eval- longer treatment before or after radiocontrast adminis-
uated in the prevention of contrast nephropathy before tration has not been explored for this clinical end point.
abandoning the development of ET receptor antagonists
Andrew Wang and Steven J. Schwabin the treatment of acute renal failure.
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